CO · Global Cord Blood Corp

Global Cord Blood Corporation is currently in a long term uptrend where the price is trading 17.1% above its 200 day moving average.

From a valuation standpoint, the stock is 99.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.2.

Global Cord Blood Corporation's total revenue sank by 13.1% to $291M since the same quarter in the previous year.

Its net income has dropped by 19.6% to $117M since the same quarter in the previous year.

Finally, its free cash flow grew by inf% to $624M since the same quarter in the previous year.

Based on the above factors, Global Cord Blood Corporation gets an overall score of 3/5.